drugset / Trial / NCT01102673

Single Dose Study of PF-04991532 in Healthy Subjects

NCT01102673

Phase 1 Completed 18 enrolled Pfizer
RandomizedCrossoverDouble-blind

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK) and preliminary food effect of PF-04991532 following single escalating oral doses in healthy adult subjects.

Timeline

Start
2010-04
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-04991532 Small molecule 30 mg Oral
Subject PF-04991532 Small molecule 100 mg Oral
Subject PF-04991532 Small molecule 300 mg Oral
Subject PF-04991532 Small molecule 600 mg Oral
Subject PF-04991532 Small molecule 1200 mg Oral
Subject PF-04991532 Small molecule 2000 mg Oral